Gestational Diabetes Diagnosed at Lower Blood Glucose Levels
A new international study involving 23,000 women in nine countries suggests that more than twice as many mothers to be as previously thought will develop gestational diabetes. This finding is based on new measurements for determining dangerous blood sugar levels for the mother and her unborn baby. Previous guidelines to diagnose gestational diabetes were based on blood sugar levels that identified women...
Amylin Lilly Logo
Lilly and Amylin Confirm FDA Extension of Exenatide Once Weekly New Drug Application Review
The Food and Drug Administration (FDA) announced that following the closure of FDA building due to extreme weather it was granting a five day extension for the review of Amylin Pharmaceuticals Inc and Eli Lilly and Co's Exenatide Once Weekly New Drug Application. The new drug is part of a collaboration between the companies started in 2002, which includes the currently available twice daily type 2 diabetes drug...
gsk-logo
GSK Rejects Allegation Regarding Avandia Safety
GlaxoSmithKline (GSK) responded to the recently released Senate Committee on Finance report regarding Avandia. GSK said it rejects any allegations of concealing safety information or acting inappropriately on behalf of patients. GSK also said it disagrees with the Committee’s decision to publish a Staff Report with the errors of fact, omissions, and inferences detailed in GSK’s White Paper....
Avandia and Heart Disease – part 2
In the previous post we looked at some possible mechanisms which could contribute to Avandia’s issues with cardiac events. Here I would like to…
On the Road to Rotterdam
A few weeks ago I received a notice announcing that the marathon had been postponed from March 26th to May 13th...
Artificial Sweeteners, A to Z
I’ll admit it: I have a Splenda habit. I’ve tried Stevia, I’ve experimented with agave, but at the end of the day I always find…
Amylin logo
Amylin and Takeda Advance Development of New Obesity Treatment
Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited announced that following positive phase 2 study results in a new obesity treatment, they will advance towards phase 3 development of a combination treatment for obesity which includes pramlintide (an analog of the natural hormone amylin) and metreleptin (an analog of the natural hormone leptin)...